Empirical Financial Services LLC d.b.a. Empirical Wealth Management Acquires New Position in PTC Therapeutics, Inc. $PTCT

Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) during the third quarter, HoldingsChannel reports. The firm bought 20,775 shares of the biopharmaceutical company’s stock, valued at approximately $1,275,000.

Several other hedge funds also recently made changes to their positions in PTCT. Empowered Funds LLC acquired a new stake in shares of PTC Therapeutics during the 1st quarter valued at approximately $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in PTC Therapeutics by 11.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock valued at $9,109,000 after purchasing an additional 18,504 shares during the last quarter. AlphaQuest LLC raised its holdings in shares of PTC Therapeutics by 337.7% during the second quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 6,102 shares during the period. State of New Jersey Common Pension Fund D lifted its position in shares of PTC Therapeutics by 7.0% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 41,376 shares of the biopharmaceutical company’s stock worth $2,021,000 after buying an additional 2,701 shares during the last quarter. Finally, Brighton Jones LLC bought a new position in shares of PTC Therapeutics in the 2nd quarter worth about $226,000.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Insider Buying and Selling

In related news, insider Eric Pauwels sold 3,019 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total transaction of $209,397.84. Following the sale, the insider owned 77,122 shares of the company’s stock, valued at $5,349,181.92. The trade was a 3.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Pierre Gravier sold 2,992 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $207,525.12. Following the completion of the sale, the chief financial officer owned 87,318 shares of the company’s stock, valued at $6,056,376.48. This trade represents a 3.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 250,873 shares of company stock worth $19,595,975. Company insiders own 5.50% of the company’s stock.

Analysts Set New Price Targets

PTCT has been the subject of a number of recent research reports. TD Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Bank of America lowered their target price on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a report on Friday. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada lowered their price objective on PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating for the company in a research note on Friday. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $90.00 target price on shares of PTC Therapeutics in a research note on Thursday, January 8th. Ten investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $80.73.

PTC Therapeutics Stock Performance

Shares of PTCT opened at $70.66 on Monday. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $87.50. The stock’s fifty day moving average is $74.91 and its 200-day moving average is $68.14. The firm has a market capitalization of $5.85 billion, a price-to-earnings ratio of 9.13 and a beta of 0.48.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The company had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The business’s revenue for the quarter was down 22.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.85) EPS. Analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.